CLYDE BIOSCIENCES LIMITEDActive
Key figures
Like most small UK companies, CLYDE BIOSCIENCES LIMITED does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.
Balance sheet structure
Filed accounts2019/20–2024/25
| 2020/21 | 2021/22 | 2022/23 | 2023/24 | 2024/25 | |
|---|---|---|---|---|---|
| Cash at bank and in hand | 157,341 | 224,940 | 228,223 | 164,761 | 220,857 |
| Total assets | — | — | — | — | — |
| Total liabilities | — | — | — | — | — |
| Net assets / total equity | -1,244,960 | -1,278,858 | -1,542,172 | -1,680,195 | -1,585,061 |
| Average number of employees | 6 | 6 | 7 | 9 | 9 |
A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.
Principal activity
Accounts 2025The principal activity of the Company during the financial year was to test for cardiotoxicity risk and improve the safety profile of both existing and new pharmaceutical products.
As described in the company's latest filed accounts.
Summary: CLYDE BIOSCIENCES LIMITED
Company
CLYDE BIOSCIENCES LIMITED is a private limited company registered with Companies House under company number SC418838. It was incorporated on 7 Mar 2012. Its status is active. The registered office is in Motherwell (ML1). Its nature of business (SIC 2007) is research and experimental development on biotechnology (72110).
Accounts
The latest accounts in the database are for 2024/25 (period ending 31 Jul 2025); the company files small company accounts (filleted). Net assets were −£1,585,061, up 5.7% on the previous year. Cash at bank and in hand was £220,857. The company had an average of 9 employees. Figures are available for 6 financial years (2019/20–2024/25).
Control and charges
One person with significant control is registered. 2 of 2 registered charges are outstanding.
Filing deadlines
The next accounts are due by 30 Apr 2027. The next confirmation statement is due by 12 Mar 2027.